Impact of body mass index on immunogenicity of pandemic H1N1 vaccine in children and adults.

Callahan ST, Wolff M, Hill HR, Edwards KM, NIAID Vaccine and Treatment Evaluation Unit (VTEU) Pandemic H1N1 Vaccine Study Group
J Infect Dis. 2014 210 (8): 1270-4

PMID: 24795475 · PMCID: PMC4271072 · DOI:10.1093/infdis/jiu245

Obesity emerged as a risk factor for morbidity and mortality related to 2009 pandemic influenza A (H1N1) infection. However, few studies examine the immune responses to H1N1 vaccine among children and adults of various body mass indices (BMI). Pooling data from 3 trials of unadjuvanted split-virus H1N1 A/California/07/2009 influenza vaccines, we analyzed serologic responses of participants stratified by BMI grouping. A single vaccine dose produced higher hemagglutination inhibition antibody titers at day 21 in obese compared to nonobese adults, but there were no significant differences in responses to H1N1 vaccine among children or adults of various BMI following 2 doses.

© The Author 2014. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail:

MeSH Terms (13)

Adolescent Adult Aged Body Mass Index Child Child, Preschool Humans Infant Influenza, Human Influenza A Virus, H1N1 Subtype Influenza Vaccines Middle Aged Young Adult

Connections (1)

This publication is referenced by other Labnodes entities: